New gel could ease chemo nerve pain without addiction risks
NCT ID NCT07072468
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a gel called VMD-3866 for pain from chemotherapy-induced peripheral neuropathy (CIPN). It is applied to the skin and works by blocking pain signals in nerves. The trial includes 16 adults with stable CIPN pain for at least 3 months. Researchers compare the gel to a placebo to see if it safely reduces pain without entering the brain or causing addiction.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hammersmith Medicines Research Ltd (HMR code 24-503)
RECRUITINGLondon, UK, NW10 7EW, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Smartwatch could spot nerve damage before it starts
- Could simple leg exercises restore balance and blood flow after chemotherapy?
- Could a simple vibrating pad ease chemo nerve damage?
- Blood test may predict nerve damage from common chemo drug
- Could light therapy ease Chemo's nerve pain?